Search results
Results from the WOW.Com Content Network
Ensitrelvir is being studied for its potential use as post-exposure prophylaxis (PEP) after SARS-CoV-2 exposure. [19] [20] The SCORPIO-PEP trial is a global Phase 3 trial that will evaluate the safety and efficacy of the drug in preventing symptomatic SARS-CoV-2 infection in household contacts of people who tested positive for COVID-19.
If taking Paxlovid, some side effects, according to the treatment’s fact sheet, could include allergic reactions, liver problems, nausea, high blood pressure, altered sense of taste and ...
Nirmatrelvir/ritonavir is under investigation, so its side effects have yet to be fully evaluated and may not be completely known. [19] Other side effects of nirmatrelvir/ritonavir may include hypersensitivity reactions, liver toxicity, and development of HIV drug resistance in people with uncontrolled or undiagnosed HIV infection.
The most common side effect in people with COVID‑19 is nausea. [13] Side effects may include liver inflammation and an infusion-related reaction with nausea, low blood pressure, and sweating. [24] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [25]
When the antiviral medication Paxlovid was approved in 2021 to treat COVID-19, doctors began noticing a trend among some patients: a rebound case of the virus. After treatment, some people would ...
In March 2022, the BBC wrote, "There are now many drugs that target the virus or our body in different ways: anti-inflammatory drugs that stop our immune system overreacting with deadly consequences, anti-viral drugs that make it harder for the coronavirus to replicate inside the body and antibody therapies that mimic our own immune system to ...
Pharmacists can now prescribe the COVID-19 treatment pill Paxlovid— the antiviral medication created by Pfizer — at pharmacies throughout the U.S., the Food and Drug Administration announced ...
The general idea behind modern antiviral drug design is to identify viral proteins, or parts of proteins, that can be disabled. [11] [13] These "targets" should generally be as unlike any proteins or parts of proteins in humans as possible, to reduce the likelihood of side effects and toxicity. [8]